MARKET WIREBenzinga • 2d ago
This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For FridayAnalysts initiated coverage with Buy/Overweight ratings on KZIA ($27), PSQL ($12), NSRX ($7) and LGCY ($16).
Why NSRX Stock dropped -4.49% Today — RQD Quant Desk Flash
$3.19 -4.49% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.16
Nasus Pharma Ltd. (NSRX) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $37.4M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on NSRX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is NSRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Nasus Pharma Ltd. (NYSE: NSRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $3.19 (-4.49% 1D, market cap $37.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NSRX ranks #793 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does NSRX compare to VERU and NNVC in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NSRX carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VERU (Veru Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $38.0M) and NNVC (NanoViricides Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $36.5M). Among the 5-stock peer group, NSRX leads on earnings multiple (N/A) while NSRX leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for NSRX?
▼
Per NSRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002029039), Nasus Pharma Ltd. generated $1.24B in revenue, -$5.9M in net income, and -$4.9M in free cash flow against $5.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.16 (-1.00%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-10% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NSRX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY NSRX SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+10/20 pts (28% of score)
FRED Regime × Technicals: 16% of 52W Range • RSI-14 at 38.3 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (22% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$3.51-9.4% Next Q
44
Q2 (-2Q)Grade D$3.18+9.7% Next Q
41
Q3 (-1Q)Grade E$3.49-8.6% Next Q
39
CurrentGrade D-$3.19-8.3% Hist 90D α
36
Trajectory: D (44) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a NSRX Turnaround Squeeze
While NSRX currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.58) and Max Pain ($3.35) forces dealer call-delta covering toward $9.97.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NSRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NSRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NSRX Stock dropped -4.49% Today — RQD Quant Desk Flash
Nasus Pharma Ltd. (NSRX) dropped -4.49% to $3.19, trading at 16% of its 52-week range ($1.98 – $9.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 16% of its 52-week range ($1.98 – $9.5) with RSI-14 at 38.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $3.19 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live NSRX Headlines & Catalysts
MARKET WIREBenzinga • 2d ago
Maxim Group Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $7Maxim Group analyst Naz Rahman initiates coverage on Nasus Pharma (AMEX:NSRX) with a Buy rating and announces Price Target of $7.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NSRX)
- ✓Walkthrough of NSRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NSRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +18.15%🛡️ HOLDING TREND SUPPORT
2026-10-30O $3.23H $3.27L $3.07C $3.19VOL 4.9K
RES: $4.10SUP: $3.05SMA50: $3.58SMA200: $3.64
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NSRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on NSRX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NSRX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NSRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NSRX)
Health Care Rank #793 of 1016
⚔️ VERU vs NSRX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NSRX vs. VERU, NNVC, EDSA, SCYX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Nasus Pharma Ltd. (NSRX) ranks #793 by composite RQD confidence (36/100, grade D-) and #783 by equity capitalization ($37.4M). Within this direct 5-issuer industry benchmark cohort, NSRX leads on earnings valuation at N/A trailing P/E, while NSRX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VERU currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with NSRX at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NSRX
ACTIVE
Nasus Pharma Ltd. | D- | 36/100 | — | — | -35.0% | -4.49% | $37.4M | Benchmark Subject |
| VERU Veru Inc. | D- | 43/100 | — | — | -35.0% | -1.76% | $38.0M | /veru-vs-nsrx → |
| NNVC NanoViricides Inc. | E | 33/100 | — | — | -35.0% | -1.38% | $36.5M | /nnvc-vs-nsrx → |
| EDSA Edesa Biotech Inc. | D- | 42/100 | — | — | -35.0% | +5.47% | $36.5M | /edsa-vs-nsrx → |
| SCYX SCYNEXIS Inc. | E | 34/100 | — | — | -35.0% | -2.28% | $38.4M | /scyx-vs-nsrx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002029039In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nasus Pharma Ltd. (NSRX) reported GAAP revenue of $1.24B (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$5.9M, operating cash flow of -$4.9M, and free cash flow of -$4.9M (-641.7% YoY). On the balance sheet, NSRX closed FY2025 with $5.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.24B | -$5.9M | -$4.9M | -$4.9M | $5.0M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$1.5M | -$665.0K | -$665.0K | $717.0K | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$1.1M | -$1.0M | -$1.0M | — | — |
3. NSRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NSRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Nasus Pharma Ltd. (NYSE: NSRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $3.19 (-4.49% 1D, market cap $37.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NSRX ranks #793 in composite RQD confidence.
How does NSRX compare to VERU and NNVC in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NSRX carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VERU (Veru Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $38.0M) and NNVC (NanoViricides Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $36.5M). Among the 5-stock peer group, NSRX leads on earnings multiple (N/A) while NSRX leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NSRX?
Per NSRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002029039), Nasus Pharma Ltd. generated $1.24B in revenue, -$5.9M in net income, and -$4.9M in free cash flow against $5.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NSRX trading relative to its 50-day, 200-day, and 52-week technical levels?
NSRX last traded at $3.19 (-4.49% on volume of 10,578 shares), positioning the stock -10.89% below its 50-day simple moving average ($3.58) and -12.36% below its 200-day simple moving average ($3.64). Across its 52-week range of $1.98 to $9.50, NSRX sits at the 16.1% percentile with a 14-day RSI of 38.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.79 to $3.59).
NSRX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is NSRX stock moving today?
Why NSRX Stock dropped -4.49% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.